CCM
CSTL icon

Coldstream Capital Management’s Castle Biosciences CSTL Stock Holding History

Coldstream Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-342
Closed -$6.85K – 1632
2025
Q1 		$6.85K Buy
+342
New +$8.47K ﹤0.01% 2543

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Coldstream Capital Management's CSTL Position: Q2 2025 in Review

Coldstream Capital Management sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 342 shares — an estimated $6.85K sold.

Coldstream Capital Management first reported a position in CSTL in Q1 2025 and held it in 1 quarter. The position peaked at $6.85K in Q1 2025. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Coldstream Capital Management reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 342 Castle Biosciences shares in Q2 2025, an estimated $6.85K.
  • Coldstream Capital Management first reported a position in Castle Biosciences in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Castle Biosciences position peaked at $6.85K in Q1 2025.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.